Clovis Oncology to Highlight Results from Rucaparib TRITON Prostate Program at ESMO 2018 Congress

San Francisco, CA USA ( -- Clovis Oncology, Inc. announced that four posters featuring data and highlighting studies from the Rubraca® clinical development program will be presented at the ESMO 2018 Congress (European Society for Medical Oncology), 19-23 October, 2018, in Munich, Germany. These posters include the first presentation of initial results from the Phase 2 TRITON2 clinical trial of Rubraca, an oral, small molecule PARP inhibitor, in advanced mCRPC, as well as genomic profiling data based on tumor tissue and plasma cfDNA samples from patients who were screened following progression on prior therapy for enrollment in TRITON2 or the Phase 3 TRITON3 clinical study. Both datasets from the TRITON clinical program have been selected for inclusion in a poster discussion session that will be led by invited discussant Dr. Joaquin Mateo, of the Prostate Cancer Translational Research Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain.

TRITON2 is an international, multicenter, open-label, Phase 2 study of Rubraca in men with advanced prostate cancer with BRCA gene mutations (germline or somatic) or other deleterious mutations in other homologous recombination (HR) repair genes in the metastatic castration-resistant setting. The study is currently recruiting at approximately 100 sites worldwide. On October 2, 2018, Clovis announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation for Rubraca for the treatment of adult patients with BRCA1/2-mutated mCRPC who have received at least one prior androgen receptor (AR)-directed therapy and taxane-based chemotherapy. The FDA granted this designation based on the initial efficacy and safety results from TRITON2 that will be shared at the ESMO 2018 Congress.

“We look forward to presenting a first look at the TRITON2 prostate cancer data at ESMO, with a primary focus on the BRCA mutant population,” said Patrick J. Mahaffy, President, and CEO of Clovis Oncology. “The data and updates we will share at ESMO emphasize our commitment to developing Rubraca beyond its initial ovarian cancer indications.”
The four Rubraca abstracts from Clovis Oncology that have been accepted for poster presentation at the ESMO 2018 Congress are:

Title: ARIEL3: Subgroup analysis of rucaparib in platinum-sensitive recurrent ovarian carcinoma: effect of prior chemotherapy regimens (abstract 947P)
Presenter: Dr. Domenica Lorusso, Unità di Ginecologia Oncologica, Fondazione IRCCS Istituto Nazionale dei Tumori and MITO, Milan, Italy
Session: Poster session
Date/Time: Saturday, 20 October, 12:30–13:30 CEST
Location: Hall A3

Title: Preliminary results from TRITON2: a phase 2 study of rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations (abstract 793PD)
Presenter: Dr. Wassim Abida, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Session: Poster discussion session, genitourinary tumors, prostate
Date/Time: Sunday, 21 October, 09:15–10:30 CEST
Location: Room 14b

As the subject of a poster discussion session, this poster will be on display for the duration of the congress beginning at 9:00 CEST on Saturday, 20 October 2018.

Title: TRITON: Genomic profiling of circulating tumour DNA (ctDNA) and tumour tissue for the evaluation of rucaparib in metastatic castration-resistant prostate cancer (mCRPC) (abstract 795PD)
Presenter: Dr. Simon Chowdhury, Guy’s Hospital & Sarah Cannon Research Institute, London, UK
Session: Poster discussion session, genitourinary tumours, prostate
Date/Time: Sunday, 21 October, 09:15–10:30 CEST
Location: Room 14b
As the subject of a poster discussion session, this poster will be on display for the duration of the congress beginning at 9:00 CEST on Saturday, 20 October 2018.

Title: ATLAS: a phase 2, open-label study of rucaparib in patients with locally advanced (unresectable) or metastatic urothelial carcinoma (abstract 928TIP)
Presenter: Dr. Simon Chowdhury, Guy's Hospital & Sarah Cannon Research Institute, London, UK
Session: Poster session
Date/Time: Monday, 22 October, 13:15–14:15 CEST
Location: Hall A3

Specific program times and locations are subject to change by ESMO.

Further Related Content:
Complete ESMO 2018 Conference Coverage